HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.

Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the most promising anti-cancer agents, but some tumor types develop resistance to TRAIL. Here, we report that chetomin, an inhibitor of hypoxia-inducible factors, is a potent enhancer of TRAIL-induced apoptosis. TRAIL or chetomin alone weakly induced apoptosis, but the combination of chetomin and TRAIL synergistically induced apoptosis in prostate cancer PC-3 cells. The combination of chetomin and TRAIL induces the activation of caspase-3, -8, -9 and -10. Among the apoptotic factors related to the TRAIL pathway, chetomin markedly decreased the X-linked inhibitor of apoptosis (XIAP) protein levels in a dose-dependent manner, but other IAP family members, TRAIL receptors and Bcl-2 family members were not altered by chetomin. Using XIAP siRNA instead of chetomin, down-regulation of XIAP sensitized PC-3 cells to TRAIL-induced apoptosis. Conversely, transient transfection of XIAP reduced the apoptotic response to combined treatment with chetomin and TRAIL. Treatment with chetomin induced a rapid decrease in XIAP protein levels but had no effect on XIAP mRNA levels. Since chetomin-mediated XIAP down-regulation was completely prevented by proteasome inhibitors, it was suggested that chetomin induces the degradation of the XIAP protein in a proteasome-dependent manner. Additionally, chetomin also sensitized renal cancer Caki-1 cells and bladder cancer UM-UC-3 cells to TRAIL-induced apoptosis via down-regulation of XIAP. Co-treatment of chetomin and TRAIL did not enhance apoptosis in normal peripheral blood mononuclear cells (PBMC). Taken together, these findings suggest that TRAIL and chetomin synergistically induce apoptosis in human urogenital cancer cells through a mechanism that involves XIAP down-regulation by chetomin.
AuthorsKimihiro Yano, Mano Horinaka, Tatsushi Yoshida, Takashi Yasuda, Hiroya Taniguchi, Ahmed E Goda, Miki Wakada, Sae Yoshikawa, Terukazu Nakamura, Akihiro Kawauchi, Tsuneharu Miki, Toshiyuki Sakai
JournalInternational journal of oncology (Int J Oncol) Vol. 38 Issue 2 Pg. 365-74 (Feb 2011) ISSN: 1791-2423 [Electronic] Greece
PMID21165560 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Disulfides
  • Indole Alkaloids
  • Mycotoxins
  • RNA, Messenger
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • TNF-Related Apoptosis-Inducing Ligand
  • X-Linked Inhibitor of Apoptosis Protein
  • XIAP protein, human
  • chetomin
  • Caspases
Topics
  • Apoptosis (drug effects)
  • Blotting, Western
  • Caspases (metabolism)
  • Cell Proliferation (drug effects)
  • Disulfides (pharmacology)
  • Drug Synergism
  • Humans
  • Indole Alkaloids (pharmacology)
  • Kidney Neoplasms (metabolism, pathology, therapy)
  • Male
  • Mycotoxins (pharmacology)
  • Prostatic Neoplasms (metabolism, pathology, therapy)
  • RNA, Messenger (genetics)
  • Receptors, TNF-Related Apoptosis-Inducing Ligand (metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction
  • TNF-Related Apoptosis-Inducing Ligand (pharmacology)
  • Tumor Cells, Cultured
  • Urinary Bladder Neoplasms (metabolism, pathology, therapy)
  • X-Linked Inhibitor of Apoptosis Protein (antagonists & inhibitors, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: